Figure 2.

Depth of response for 70 patients with measurable advanced esophageal squamous cell carcinoma, with clinical features. The waterfall plots show the percentage reduction in tumor burden from baseline, with red bars representing nivolumab (nivo) + chemotherapy (chemo), blue bars indicating pembrolizumab + chemo, and green bars representing nivo + ipilimumab (nivo + ipi) treatment. DpR, depth of response; ETS, early tumor shrinkage; OS, overall survival; pem, pembrolizumab; PFS, progression-free survival; RT, prior radiotherapy; TPS, tumor proportion score.